Creation of SPINOFF COMPANIES

Since the year 2000, ALIGO has played a role in creating over 71 Quebec-based technology companies. Of these 71 companies, 43 are still active, which equates to 61%, one of the highest percentages seen in this field. The 43 companies which are still active today have generated over $522 million in investments. The following image presents the companies in accordance with the size of their investments, both public and private.

Spinoff companies means:

  • A company incorporated for the main purpose of operating a license for a technology that Aligo is developing and which comes from an establishment that Aligo represents;
  • An already existing company that refocuses its activities around a license obtained from a technology that is valued by Aligo and that comes from an establishment that Aligo represents.

Representation on March 31, 2019

OUR SPINOFF COMPANIES

Inolife

Inolife Sciences is an emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies. Inolife commercializes patented and FDA-cleared needle-free injection devices.

Resonnant Medical (Acquired by Elekta)

The treatment solutions and oncology informatics portfolios of Resonnant Medical are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows.

Emovi

Emovi is dedicated to providing the highest quality, most technologically advanced products for knee joint assessment to restore patient quality of life.

Ovensa

Ovensa is a preclinical stage company working to fight inherent therapeutic resistance in complex diseases by generating advanced nanotherapeutics through its proprietary TRIOZAN™ Platform. The company focuses on advancing its lead nanotherapeutic candidate that synergistically improves efficacy of chemotherapy and checkpoint inhibitors in glioblastoma.

DropGenie

DropGenie is a biotechnology company developing a platform that automates liquid handling and experimental conditions specific to genetic engineering, thus reducing costs while improving standardization and reproducibility. With the rapid adoption of CRISPR technology, their product will initially target R&D applications by easing gene editing in human cells, followed by a longer term translational vision to develop point of care cell therapy for patients.

Luma Life

LUMA Life is a private company that develops and markets patented and scientifically proven products for the health, fitness and beauty markets.

Mimetogen Pharmaceuticals

Mimetogen Pharmaceuticals is a clinical stage biotechnology company focused on developing the use of peptidomimetics as a novel approach to treating ophthalmic diseases with high unmet medical needs.

Reflex Photonics (Acquired by Smiths Interconnect)

Reflex Photonics is an advanced developer of rugged high-speed optical transceiver modules and parallel embedded optics products for aerospace, defense, avionics, telecom, and data centers. Their products enable equipment developers to design smaller, lower cost, and lower powered systems resulting in higher fidelity and faster connectivity.

SoundBite

SoundBite Medical is a medical devices company developing and commercializing proprietary wire-based device and generator console that delivers safe shockwave energy within the cardiovascular system to treat chronic total occlusions (CTO's).

Katana (Acquired by Theratechnologies)

Katana is a pre-clinical stage biopharmaceutical company developing novel and peptide-anticancer drug conjugates for personalized and targeted therapies.

Moxxi

The MOXXI system is an integrated solution created for primary care physicians. The electronic prescribing and computerized drug management system provides personalized care suited to a patient’s specific needs and ensures that his/her drugs are managed safely and effectively.

IR&T

IR&T develops LabPET II scanners currently achieving the best spatial resolution for PET imaging of small animals

Tri-Onco

Tri-Onco is a pre-clinical stage biopharmaceutical company developing small molecules for the treatment of inflammatory cancers such as bladder and breast cancers.

Molecular Forecaster

Molecular Forecaster Inc. is a leading scientific company that distributes the FORECASTER (platform for drug design and discovery) and VIRTUAL CHEMIST (platform for virtual combinatorial chemistry and catalyst discovery) and offers research contract services.

NexPlasmagen

NexPlasmaGen Inc. is a company applying cold plasma biotechnologies to the treatment of cancer, striving to reduce radiation-related side-effects, while improving patient outcomes.

Milestone Pharmaceuticals

Milestone is a clinical-stage pharmaceutical company developing novel small molecule therapeutics based on clinically-validated mechanisms of action for cardiovascular diseases.

MIMs

MIMsOmic is an AI platform built for managing massive amounts of knowledge in life sciences aggregated from public databases. MIMsOmic uses this knowledge and considers the data and associated metadata uploaded by the user to run the appropriate bioinformatic and machine learning algorithms to capture key insights, patterns and trends from data.

Laurent Pharmaceuticals

Laurent Pharmaceuticals is a private biopharmaceutical company developing a clinical-stage, orally-active drug candidate with potential to modulate the immuno-inflammatory response in Cystic Fibrosis patients.

Chiono Biopharma

Chiono Biopharma is a pre-clinical stage company using crab hemocyanin issued from snow crab waste as an adjuvant for the preparation of vaccine and therapeutic antibodies.

Guzzo Nano Research

Guzzo Nano Research develops new nano-therapeutics platform for targeted tumor photo-ablation and imaging - circumventing genetic heterogeneity and the development of cancer drug resistance.

Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the blood-brain-barrier to treat neurological diseases.

Orixha

Orixha has developped an innovative device for cooling patients within few minutes and thus improve their prognosis by using a dedicated liquid ventilator able to perform safe and efficient total liquid ventilation inducing therapeutic hypothermia after cardiac arrest.

Donec quis, mi, in et, Phasellus accumsan at id dapibus